<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662528</url>
  </required_header>
  <id_info>
    <org_study_id>MAT-003</org_study_id>
    <nct_id>NCT04662528</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and &lt;2000 mg/dL</brief_title>
  <acronym>AMPLIFY</acronym>
  <official_title>A Phase 3, Placebo-Controlled, Randomized, Double-blind, Parallel-arm Trial to Assess the Safety and Efficacy of MAT9001 in Subjects With Severe Hypertriglyceridemia: The AMPLIFY Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matinas Biopharma, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Matinas Biopharma, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of MAT9001 compared to placebo in lowering fasting triglyceride&#xD;
      levels in subjects with very high fasting triglyceride levels ≥ 500 and &lt; 2000 mg/dL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 12-week, randomized, double blind, placebo-controlled safety and efficacy&#xD;
      study in men and women ≥18 years of age with fasting triglycerides ≥500 mg/dL and &lt;2000 mg/dL&#xD;
      while following a Therapeutic Lifestyle changes (TLC) diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    suspended&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent change from baseline to end of study for MAT9001 versus Placebo</measure>
    <time_frame>12 weeks</time_frame>
    <description>Difference between MAT9001 and placebo treatment groups in triglyceride lowering effect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percent change from baseline to end of study for lipids and lipid biomarkers for MAT9001 versus Placebo</measure>
    <time_frame>12 weeks</time_frame>
    <description>Difference between MAT9001 and placebo treatment groups in other lipid and biomarker levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Severe Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAT9001 (omega-3-pentaenoic acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 x 1g capsules/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAT9001 (omega-3 pentaenoic acid)</intervention_name>
    <description>4 x 1g capsules/day</description>
    <arm_group_label>MAT9001 (omega-3-pentaenoic acid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fasting triglycerides ≥500 mg/dL and &lt;2000 mg/dL&#xD;
&#xD;
          -  Stable lipid-altering drug therapies permitted&#xD;
&#xD;
          -  Stable PCSK9 inhibitor use permitted&#xD;
&#xD;
          -  BMI ≥20.0 kg/m2&#xD;
&#xD;
          -  Willing to maintain a Therapeutic Life Change diet for the duration of the study&#xD;
&#xD;
          -  willing to maintain usual physical activity level for the duration of the study&#xD;
&#xD;
          -  willing to abstain from alcohol consumption for at least 24 hours prior to each study&#xD;
             visit&#xD;
&#xD;
          -  agrees not to consume more than 2 meals/week containing fish or seafood&#xD;
&#xD;
          -  no plans to change smoking/vaping habits or other nicotine use during the study period&#xD;
&#xD;
          -  to be in generally good health on the basis of medical history, physical exam,&#xD;
             electrocardiogram (ECG), and screening measurements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory test result of clinical significance based on the judgment of the Principal&#xD;
             Investigator&#xD;
&#xD;
          -  A clinically significant GI, endocrine, cardiovascular, renal, hepatic, pulmonary,&#xD;
             pancreatic, neurologic, or biliary disorder&#xD;
&#xD;
          -  Known lipoprotein lipase impairment or deficiency or Apo C2 deficiency or familial&#xD;
             dysbetalipoproteinemia&#xD;
&#xD;
          -  Acute or chronic pancreatitis&#xD;
&#xD;
          -  Symptomatic gallstone disease (unless previously treated with cholecystectomy).&#xD;
&#xD;
          -  Known nephrotic syndrome&#xD;
&#xD;
          -  Malabsorption syndrome and/or chronic diarrhea&#xD;
&#xD;
          -  Previous bariatric surgery or weight change &gt;3 kg (6.6 lb) during the lead in period.&#xD;
&#xD;
          -  Diagnosed hereditary or acquired myopathy&#xD;
&#xD;
          -  Uncontrolled diabetes (HbA1c ≥9.5%)&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood&#xD;
             pressure ≥100 mm Hg)&#xD;
&#xD;
          -  Uncontrolled hypothyroidism, thyroid stimulating hormone &gt;5 mIU/L&#xD;
&#xD;
          -  History of cancer in the prior 2 years, except non melanoma skin cancer or carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  History of human immunodeficiency virus, hepatitis B, or hepatitis C infection.&#xD;
&#xD;
          -  Active systemic infection.&#xD;
&#xD;
          -  History of paroxysmal atrial fibrillation, persistent atrial fibrillation, and/or&#xD;
             history of ventricular tachycardic arrythmia (e.g., ventricular&#xD;
             tachycardia/fibrillation)&#xD;
&#xD;
          -  History of a bleeding disorder&#xD;
&#xD;
          -  Use of omega 3 drugs /supplements /fortified foods&#xD;
&#xD;
          -  Use of bile acid sequestrants, fibrates, or niacin&#xD;
&#xD;
          -  Use of dietary supplement(s) that alters lipid metabolism&#xD;
&#xD;
          -  Use of weight management drug therapy&#xD;
&#xD;
          -  Cardiovascular disease event (myocardial infarction or other acute coronary syndrome,&#xD;
             stroke, transient ischemic attack), revascularization procedure&#xD;
&#xD;
          -  Female who is pregnant, planning to be pregnant during the study period, lactating, or&#xD;
             is of childbearing potential and is unwilling to commit to the use of a medically&#xD;
             approved form of contraception throughout the study period&#xD;
&#xD;
          -  Known allergy or sensitivity to any ingredients in the study products, including fish,&#xD;
             seafood or omega 3 fatty acids&#xD;
&#xD;
          -  Been exposed to any investigational drug product within 30 days&#xD;
&#xD;
          -  Current or recent history or strong potential for illicit drug or excessive alcohol&#xD;
             intake&#xD;
&#xD;
          -  A condition that would interfere with ability to provide informed consent or comply&#xD;
             with the study protocol, or put the person at undue risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Johnson</last_name>
    <role>Study Director</role>
    <affiliation>Matinas BioPharma</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

